Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2010 - 2025)

Arbutus Biopharma has disclosed Non-Current Deffered Revenue across 12 years of filings, most recently posting $2.9 million for Q1 2025.

• Non-Current Deffered Revenue for Q1 2025 came in at $2.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $2.9 million (changed N/A YoY), and the FY2024 annual result was $2.9 million, changed N/A from the prior year.
• Non-Current Deffered Revenue came in at $2.9 million for Q1 2025 at Arbutus Biopharma, roughly flat from $2.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $15.6 million in Q1 2022 to a low of $2.9 million in Q4 2024.
• The 4-year median for Non-Current Deffered Revenue is $6.0 million (2022), against an average of $7.4 million.
• Peak annual rise in Non-Current Deffered Revenue reached 78.85% in 2023, while the deepest fall reached 78.85% in 2023.
• Arbutus Biopharma's Non-Current Deffered Revenue stood at $6.0 million in 2022, then slumped by 45.06% to $3.3 million in 2023, then dropped by 13.14% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $2.9 million (Q1 2025), $2.9 million (Q4 2024), and $3.3 million (Q1 2023), per Business Quant data.